Aeolus initiates phase 1 study of AEOL 10150 in healthy normal volunteers
Aeolus Pharma announced initiation of a phase 1 study with its lead compound AEOL 10150. The phase 1 study is an open-label, single center, dose‑escalation study to evaluate safety, tolerability, and pharmacokinetics of an escalating single dose of AEOL 10150 administered by subcutaneous injection. February 22, 2017